Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00843011 | Food and Relative Bioavailability Study | PHASE1 | COMPLETED | 14 | — | — | Aug 28, 2008 | Oct 23, 2008 | Jul 21, 2017 | 1 | Italy |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Orvepitant 60 mg |
| Name | Type | Description |
|---|---|---|
| Orvepitant | DRUG | Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food. |
Inclusion Criteria: * Healthy male or female between 18 and 65 years of age inclusive. * A female subject is eligible to participate if she is of either non-childbearing potential or child-bearing potential and agrees to use one of the contraception methods * No co-morbid Psychiatric Disorders as d...